BANK VONTOBEL/CALL/ROCHE GS/310/0.1/21.06.24 Share Price

Warrant

DE000VV51K53

Delayed Deutsche Boerse AG 11:34:33 17/05/2024 pm IST
0.001 EUR 0.00% Intraday chart for BANK VONTOBEL/CALL/ROCHE GS/310/0.1/21.06.24
6 months-98.57%
Current year-98.55%
Date Price Change
17/24/17 0.001 0.00%
16/24/16 0.001 0.00%
15/24/15 0.001 0.00%
14/24/14 0.001 0.00%
13/24/13 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 17, 2024 at 11:34 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VV51K5
ISINDE000VV51K53
Date issued 02/08/2022
Strike 310 CHF
Maturity 21/06/2024 (32 Days)
Parity 10 : 1
Emission price 3.15
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.87
Lowest since issue 0.001
Spread 0.069
Spread %98.57%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW